The approval of immune checkpoints inhibitors (ie the anti‐PD‐1 and anti‐CTLA‐4 mAbs) and, for BRAF mutated melanoma (approximately 50% of all cases), of BRAF/MEK kinase inhibitors has dramatically improved the outcome of patients with metastases.17, 18 Unfortunately, in the case of immune checkpoint inhibitors a significant proportion of patients derive no benefit from these therapies (primary resistance), whereas in the case of BRAF/MEK inhibitors most patients respond to treatment but responses are short‐lived because of the development of drug resistance and tumour recurrence. This evidence concerns the gene MAP2K7 and neoplasm.